Alan Yeung, MD
Academic Appointments
- Professor - Med Center Line, Medicine - Cardiovascular Medicine
Key Documents
Contact Information
-
Clinical Offices
Cardiovascular Medicine Clinic 300 Pasteur Dr MC 5319 A260 Stanford, CA 94305 Tel Work (650) 723-0180 Fax (650) 725-6766
- Academic Offices
Personal Information Email Tel (650) 723-0180Alternate Contact Tanya Carrasco Administrative Assistant Email Tel Work 650-723-0180Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Cardiology (Heart)
- Cardiovascular Disease
- Coronary Artery Disease
- Chronic Total Occlusions
- Complex Coronary Angioplasty
- Mitral Valvuloplasty
Administrative Appointments
- Chief(Clinical), Division of Cardiovascular Medicine, Stanford University School of Medicine (2000 - present)
- Director, Interventional Cardiology, Stanford University School of Medicine (1998 - present)
Honors and Awards
- Li Ka Shing Professor, Stanford University (2008)
Professional Education
| Residency: | Massachusetts General Hospital MA (1987) |
| Fellowship: | Brigham and Women's Hospital, Harvard Medical School, MA USA (1990) |
| Board Certification: | Cardiovascular Disease, American Board of Internal Medicine (1989) |
| Board Certification: | Internal Medicine, American Board of Internal Medicine (1987) |
| Board Certification: | Interventional Cardiology, American Board of Internal Medicine (2000) |
| Internship: | Massachusetts General Hospital MA (1985) |
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industrial and other commercial partners. It is our policy to disclose payments (exclusive of travel support) from, and/or equity in, companies or other commercial entities to Stanford faculty of $5,000 or more in total value, as well as any equity in a privately held company, when the faculty member also has institutional responsibilities related to his or her interactions with the company. View Full Information
Scientific Focus
Current Research Interests
Coronary artery disease is the leading cause of death in men and women in the United States. Our group is interested in studying both the early and late phases of atherosclerosis so that we can better develop prevention and treatment strategies. Our current studies include:
1) non-invasive methods of assessing vascular endothelial function so that we can better stratefy high risk coronary artery disease patients.
2) structural and functional studies of atherosclerosis in transplant coronary artery disease patients in order to define the the relationship between the two.
3) intravascular ultrasound studies to define the time-course in the devlopment of transplant coronary disease.
4) development of novel techniques to devliver drug imbedded particles into the atherosclerotic wall.
5) study the restenosis process in a vivo pig model.
Clinical Trials
- Recruiting The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves
- Not Recruiting FAME II - Fractional Flow Reserve (FFR) Guided Percutaneous Coronary Intervention (PCI) Plus Optimal Medical Treatment (OMT) Verses OMT
- Not Recruiting TAXUS Libertē Post Approval Study
- Recruiting Sex Differences in Coronary Pathophysiology
Publications
- Variability in quantitative and qualitative analysis of intravascular ultrasound and frequency domain optical coherence tomography. Catheter Cardiovasc Interv. 2013
- Manganese-enhanced MRI detects live human amnion-derived mesenchymal stem cells in vivo after transplantation and restoration of myocardial function in a pig ischemia-reperfusion injury model. J Cardiovasc Magn Reson. 2012: P62
- Most accurate definition of a high femoral artery puncture: aiming to better predict retroperitoneal hematoma in percutaneous coronary intervention. Catheter Cardiovasc Interv. 2012; (1): 37-42
- Clinical evaluation of the Resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries: the RESOLUTE US clinical trial. J Am Coll Cardiol. 2011; (17): 1778-83
- Comparison of drug-eluting versus bare metal stents in cardiac allograft vasculopathy. Am J Cardiol. 2011; (5): 665-8
- Comparison of the frequency of coronary artery disease in alcohol-related versus non-alcohol-related endstage liver disease. Am J Cardiol. 2011; (11): 1552-5
Help